Evaluation and analysis of bleeding risk of anticoagulation therapy in severe non-ICU patients with COVID-19 based on heparinase-modified TEG
Journal Title: Chinese Journal of Blood Transfusion - Year 2024, Vol 37, Issue 3
Abstract
Objective To investigate the clinical application of heparinase-modified TEG (hmTEG) in evaluating coagulation status and monitoring anticoagulant therapy in severe non-ICU patients with COVID-19. Methods The clinical data of severe non-ICU patients with COVID-19 confirmed to be infected with novel coronary disease (SARS-CoV-2) from December 2022 to May 2023 were analyzed retrospectively. The patients were divided into therapeutic dose group and prophylactic dose group according to the initial dose of enoxaparin. The changes of platelet count, activated partial thromboplastin time, prothrombin time, thrombin time, fibrinogen, D-dimer, TEG and hmTEG before and after heparin treatment were compared between the two groups, so as to evaluate the changes of coagulation function and bleeding risk of COVID-19 severe non-ICU patients after anticoagulation with different doses of heparin. Results A total of 179 severe non-ICU patients with COVID-19 were enrolled in this study, including 102 patients in therapeutic dose group and 77 patients in prophylactic dose group. Before receiving heparin anticoagulation, except for age(63.4±11.6 vs 59.8±9.1) D-dimer(678 ng/mL vs 621 ng/mL) and MA values [(69.1±10.2)mm vs (65.6±8.5)mm], there were no statistical differences in platelet count, activated partial thromboplastin time, prothrombin time, thrombin time, fibrinogen, R value, K time, α angle and coagulation index (CI) between the therapeutic dose group and the prophylactic dose group (P>0.05). After receiving heparin anticoagulation, there were significant differences in CKR value [(12.2±4.1)min vs (10.2±3.3)min] and CKHR value [(8.1±3.2)min vs (7.1±2.6)min] between therapeutic dose group and prophylactic dose group (P<0.05), but no significant differences in other parameters between groups (P>0.05). Meanwhile, the proportion of heparin overdose in the therapeutic dose group was significantly higher than that in the prophylactic dose group 15.69%(16/102) vs 5.19%(4/77)(P<0.05). However, there was no difference in the incidence of VTE events 2.35 %(2/85) vs 2.78%(2/72), gastrointestinal bleeding 2.35%(2/85) vs 1.39%(1/72), ICU admission 4.71%(4/85) vs 4.17%(3/72) and death events 3.53%(3/85) vs 2.78%(2/72) between the two groups (P>0.05). Conclusion In the current epidemic trend of COVID-19, in order to reduce the occurrence of bleeding events, the heparin dose should be selected more carefully in the prevention of thrombosis in severe non-ICU patients with COVID-19. The individualized assessment of bleeding risk by hmTEG is more conducive to the adjustment and control of heparin dose.
Authors and Affiliations
Ying ZHONG, Xianwen HUANG, Chunfeng LIANG
Keywords
Related Articles
- EP ID EP738782
- DOI 10.13303/j.cjbt.issn.1004549x.2024.03.009
- Views 48
- Downloads 0
Blood transfusion strategies in patients on extracorporeal membrane oxygenation
Objective To analyze the blood transfusion strategies in extracorporeal membrane oxygenation (ECMO) recievers in our hospital, so as to explore the clinical application and efficacy of blood transfusion in patients on EC...
Screening and genotyping of Mur blood group among voluntary blood donors in the population of Hezhou, Guangxi
Objective To screen the distribution frequency of Mur blood group among voluntary blood donors in Hezhou, Guangxi, and further analyze the molecular basis of of Mur antigen positive samples. Methods The Mur phenotype of...
Value of three hemolysis tests and carboxyhemoglobin in the diagnosis of hemolytic disease of the fetus and newborn
Objective To investigate the value of three hemolysis tests and carboxyhemoglobin (COHb) level in the diagnosis of hemolytic disease of the fetus and newborn (HDFN). Methods From January 1, 2019 to December 31, 2022, the...
Research progress on iron nutritional status of plateletpheresis donors
Apheresis platelets are extensively utilized in clinical practice due to high purity and minimal side effects. These platelets are primarily obtained from regular blood donors. However, there is no consensus on whether p...
Autologous leukocyte-poor platelet-rich plasma injection in the treatment of knee osteoarthritis: short-term clinical effect analysis
Objective To investigate short-term clinical efficacy of autologous leukocyte-poor platelet-rich plasma(LP-PRP) treatment of knee osteoarthritis(KOA). Methods 85 cases of patients with Keligren Lawrence grade Ⅰ-Ⅲ knee os...